216 related articles for article (PubMed ID: 26907093)
1. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature.
Stieb S; Riesterer O; Brüssow C; Pestalozzi B; Guckenberger M; Weiler S
Strahlenther Onkol; 2016 May; 192(5):342-8. PubMed ID: 26907093
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel-induced radiation recall dermatitis : A case report and literature review.
Strouthos I; Tselis N; Zamboglou N
Strahlenther Onkol; 2016 Oct; 192(10):730-6. PubMed ID: 27287082
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Garuti F; Camelli V; Spinardi L; Bucci L; Trevisani F
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27079903
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib-induced severe urticaria in a patient with hepatocellular cancer.
Musri FY; Mutlu H; Kıvrak Salim D; Karakurt Eryılmaz M; Ünal B; Tural D; Şenol Coşkun H
J Oncol Pharm Pract; 2016 Apr; 22(2):350-3. PubMed ID: 25567520
[TBL] [Abstract][Full Text] [Related]
6. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
7. Radiation recall with vinorelbine and cisplatin.
Zhu ZF; Fan M; Fu XL
Onkologie; 2010; 33(3):107-9. PubMed ID: 20215801
[TBL] [Abstract][Full Text] [Related]
8. Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma.
Kim GE; Song HS; Ahn KJ; Kim YS
Radiat Oncol J; 2017 Sep; 35(3):289-294. PubMed ID: 29037022
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
[TBL] [Abstract][Full Text] [Related]
10. Ultraviolet recall dermatitis reaction with sorafenib.
Magné N; Chargari C; Auberdiac P; Moncharmont C; Merrouche Y; Spano JP
Invest New Drugs; 2011 Oct; 29(5):1111-3. PubMed ID: 20567994
[TBL] [Abstract][Full Text] [Related]
11. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
12. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
13. Radiation recall dermatitis induced by pazopanib.
Azad A; Maddison C; Stewart J
Onkologie; 2013; 36(11):674-6. PubMed ID: 24192773
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Li J; Hou Y; Cai XB; Liu B
World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447
[TBL] [Abstract][Full Text] [Related]
15. Successful rechallenge after ixabepilone-induced radiation recall dermatitis using an alternative dosing strategy.
Ford JN; Newton M; Jordan C; Abraham J
J Oncol Pharm Pract; 2013 Mar; 19(1):89-92. PubMed ID: 22323422
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib after RFA in HCC patients: a pilot study.
de Stefano G; Farella N; Scognamiglio U; Liorre G; Calabria G; Ascione T; Giorgio A; Iodice V
Hepatogastroenterology; 2015; 62(138):261-3. PubMed ID: 25916044
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
18. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
20. A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.
Cui T; Diao X; Chen X; Huang S; Sun J
BMC Cancer; 2016 Jul; 16():543. PubMed ID: 27465502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
